EGFR and non-small cell lung carcinoma: A phase 3 trial, AURA 3, showed that osimertinib provided significantly longer PFS than standard platinum-based chemotherapy in patients with advanced T790M-positive NSCLC who showed an acquired resistance to first-line EGFR-TKI treatment10.